Top Markets
Coin of the day
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Rang in aandelen #38382
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Aandeelprijs
$0.02468497
Marktkapitalisatie
$1.01M
Verandering (1 dag)
-12.50%
Verandering (1 jaar)
-87.34%
Land
AU
Handel Chimeric Therapeutics Limited (CHM)

Categorie

Aandelsplitsingen voor Chimeric Therapeutics Limited (CHM)
Het aandeel Chimeric Therapeutics Limited (symbool: CHM) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 14, 2026.
Eén aandeel CHM dat vóór Aug 14, 2026 werd gekocht, staat nu gelijk aan 0 aandelen CHM.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE